Neutron Therapeutics’ Accelerator Receives Final Acceptance at University of Birmingham’s High Flux Accelerator-Driven Neutron Facility
December 13, 2023 07:00 AM EST – BOSTON & BIRMINGHAM, United Kingdom (BUSINESS WIRE) – Neutron Therapeutics, a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced that its compact accelerator has received final acceptance for use at the University of Birmingham’s High Flux Accelerator-Driven Neutron Facility. This first-of-its-kind facility will enable research into the effects of neutrons in a variety of fields, including nuclear energy, nuclear science and boron neutron capture therapy (BNCT). > READ MORE
Aviko Radiopharmaceuticals and Neutron Therapeutics Form Exclusive, Strategic Partnership with Leo Cancer Care to Expand Development of Boron Neutron Capture Therapy for Treating Cancer
October 2, 2023 – NEW YORK & SAN DIEGO –Aviko Radiopharmaceuticals, a Deerfield Management-founded biotechnology company developing medicines to unlock the potential of boron neutron capture therapy (BNCT), and Neutron Therapeutics, a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced an exclusive, strategic partnership with Leo Cancer Care, a company developing upright patient positioning systems for radiation therapy. The goal of the partnership between the three companies is to expand BNCT as a potential treatment for different types of cancer. > READ MORE
Aviko Radiopharmaceuticals and Neutron Therapeutics Form Strategic Partnership to Advance Boron Neutron Capture Therapy
JUNE 8, 2023 – NEW YORK and BOSTON – (BUSINESS WIRE) – Aviko Radiopharmaceuticals, a Deerfield Management-founded biotechnology company developing medicines to unlock the potential of boron neutron capture therapy (BNCT), and Neutron Therapeutics, the leading provider of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced the formation of a strategic partnership to advance BNCT to treat cancer. The partnership aligns the companies’ efforts to build the first BNCT treatment center in the United States and to establish additional BNCT facilities through collaborations with premier academic medical centers. > READ MORE
Neutron Therapeutics Announces Successful Generation of a Neutron Beam for BNCT at Shonan Kamakura General Hospital in Japan
January 12, 2023 – BOSTON – (BUSINESS WIRE) – Neutron Therapeutics (NT), a targeted radiation oncology therapy company developing a comprehensive clinical solution for Boron Neutron Capture Therapy (BNCT), today announced the successful production of a proton beam at an industry-leading 37mA of proton current on target, and the generation of the first neutron beam at its nuBeam® system at Shonan Kamakura General Hospital (SKGH) in Kanagawa Prefecture, Japan. > READ MORE
First Completion of a Full Treatment Workflow in the First European Hospital-Based BNCT Facility
November 15, 2022 – BOSTON & LJUBLJANA, Slovenia – (BUSINESS WIRE) – Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world’s leading provider of control systems for the planet’s most complex machines, today announced that they have reached their second joint milestone in the clinical commissioning of Neutron Therapeutics’ nuBeam® BNCT System, utilizing Cosylab’s OncologyOne software, at Helsinki University Hospital – implementation of a complete treatment workflow on a patient model. > READ MORE
High-Flux Neutron Facility Launched at the University of Birmingham
September 27, 2022 – The UK’s first high-flux neutron facility has been launched at the University of Birmingham. The facility will enable scientists to study the properties of materials used in nuclear energy production, supporting the development of the UK’s next-generation nuclear energy generators. > READ MORE
Neutron Therapeutics and University Hospital of Brussels Announce Their Collaboration to Offer Cancer Patients a Revolutionary New Treatment Method at Institut Jules Bordet
June 23, 2022 – Boston & Brussels – Neutron Therapeutics, Inc (NT) and the University Hospital of Brussels (H.U.B) today announced that they have signed a Letter of Intent to place a nuBeam® suite for Boron-Neutron Capture Therapy (BNCT) at the Institut Jules Bordet (IJB), Erasmus Campus, Anderlecht. nuBeam® is the world’s safest and most powerful accelerator-based neutron source designed specifically for the hospital environment. With this agreement, H.U.B will become the third clinical center in the world to implement NT’s ground-breaking technology, enabling new therapeutic options for cancer patients. > READ MORE
First Simulated Patient Treatment Carried Out in the First Hospital-Based BNCT Facility in Europe
May 11, 2022 – Boston & Ljubljana, Slovenia – Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world’s leading provider of control systems for the planet’s most complex machines, today announced that Neutron Therapeutics’ nuBeam® BNCT System, using Cosylab’s OncologyOne software, has reached a significant milestone in its clinical commissioning at Helsinki University Hospital – first simulated patient treatment. > READ MORE
Neutron Therapeutics Ships Third High Flux Neutron Source
February 15, 2022 – Danvers, Massachusetts – We are excited to share that our latest High Flux Accelerator-Driven Neutron Source has just left our loading dock in Danvers, destined for the University of Birmingham! Installation will begin in March. > READ MORE
University of Birmingham to Open National Neutron Facility
January 13, 2022 – Birmingham, England – The High Flux Accelerator-Driven Neutron Facility will create a new international research capability and a national training programme to boost the UK skills base in these state-of-the-art techniques. > READ MORE
Neutron Therapeutics and Cosylab Announce Strategic Collaboration to Bring Boron Neutron Capture Therapy to Patients
January 11, 2022 – Boston, Massachusetts & Ljubljana, Slovenia – Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world’s leading provider of control systems for the planet’s most complex machines, today announced the close of a strategic collaboration and investment agreement to incorporate Cosylab’s OncologyOne radiation therapy product suite into Neutron’s nuBeam® BNCT systems at hospitals around the world. > READ MORE
Neutron Therapeutics Appoints Elizabeth Reczek, Ph.D., as Chief Executive Officer
December 14, 2021 – Danvers, Massachusetts – Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), announced today that it has appointed Elizabeth Reczek, Ph.D., as its Chief Executive Officer and member of its Board of Directors. > READ MORE
Kiwi Entrepreneur’s Next Big Thing: Zapping Cancer Cell-by-cell
Oct 4th, 2019 – Auckland, New Zealand – “I don’t know how many people you’ve lost to cancer, but it’s too damn many,” says Bill Buckley. Over the past four years, the 76-year-old Buckley has thrown much of his wealth – recently estimated by the NBR Rich List at $110 million – into creating a new company, Neutron Therapeutics, which aims to treat deadly tumours using Boron Neutron Capture Therapy (BNCT). > READ MORE
Neutron Therapeutics to Install its BNCT Cancer Therapy System into Japan’s Largest Private Hospital Chain
July 16th, 2019 – Danvers, Massachusetts and Tokyo, Japan – Neutron Therapeutics, Inc (NTI) has agreed with Tokushukai Medical Group (TMG) to install a nuBeam system for Boron-Neutron Capture Therapy (BNCT) at Shonan Kamakura General Hospital (SKGH) in Kanagawa Prefecture, Japan. > READ MORE
Neutron Therapeutics Installs Europe’s First Accelerator-Based Boron Neutron Capture Therapy (BNCT)
Thursday, 18th of April 2019 – Helsinki, Finland and Danvers Massachusetts. Neutron Therapeutics, Inc (NTI) has installed its compact accelerator-based neutron source for Boron Neutron Capture Therapy (BNCT) at Helsinki University Hospital (HUH). The system is currently operational and generating neutron intensity at the level recommended by the IAEA for BNCT. The HUH installation is the first accelerator-based BNCT system in Europe and the first of its kind in the world.> READ MORE
Yle News – Finland to Debut New High-powered Reactor for Cancer Treatments
Tuesday, 6th February 2018 – Helsinki, Finland. New Boron Neutron Capture Treatment in Helsinki, to be used to treat patients with recurring cancers of the head and neck. > READ MORE
HealthCare Business News – Neutron Therapeutics Partners with RaySearch Laboratories
Monday, 13th November 2017 – Danvers, Massachusetts. Neutron Therapeutics partners with RaySearch Laboratories for Neutron’s revolutionary single-room BNCT solution. RaySearch to provide extended functionality offered by RayStation’s advanced treatment planning system. > READ MORE
RaySearch Enters Into The Field Of Boron Neutron Capture Therapy
Monday, 6th November 2017 – Danvers, Massachusetts and Stockholm, Sweden. RaySearch and Neutron Therapeutics, Inc., based in Danvers, US, have entered into an agreement regarding treatment planning for boron neutron capture therapy (BNCT), which is a unique type of radiation therapy that enables targeting of cancer at the cellular level.
BNCT uses a two-step process. First, the patient is injected with a tumor-localizing drug containing the non-radioactive isotope boron-10. In the second step, the target area is exposed to a beam of low-energy neutrons, many of which are absorbed by the boron-10. The absorption initiates a reaction in which short-range, high-energy charged particles are emitted. These particles systematically destroy the tumor cells, with minimal damage to adjacent healthy tissue. > READ MORE
Novel Accelerator-Based BNCT Suite to be Delivered to a top European Cancer Hospital
Thursday, 15th September, 2016 – Danvers, Massachusetts and Helsinki, Finland – Neutron Therapeutics, Inc (NTI) and Helsinki University Hospital (HUH) have entered into an arrangement whereby HUH Cancer Center acquires a nuBeam suite for boron-neutron capture therapy (BNCT). nuBeam is a compact accelerator based neutron source which can be installed in a hospital environment. Under the arrangement NTI and HUH will collaborate in developing BNCT towards clinical use in a number of cancer indications. A biologically targeted form of radiation therapy, BNCT has previously been applied by the HUH in the treatment of severe cancer cases using a research nuclear reactor as the neutron source. > READ MORE
Revolutionary Cancer Treatment Engineered by Buckley Systems
Thursday, 15 September, 2016 – Auckland, New Zealand – Auckland precision electro magnets manufacturer, Buckley Systems is involved in the development and manufacture of the nuBeam proton accelerator machine for an alternative cancer treatment that has been announced overnight in Helsinki, Finland. Boron Neutron Capture Therapy is not a new treatment, but making it a practical proposition has only been possible as a result of co-operation between Buckley Systems and engineers who used to work for GT Advanced Technologies in Danvers, Massachusetts and a Helsinki medical team. A new company, Neutron Therapeutics, has been set up to make the technology viable as a compact, affordable and hospital ready source for a single neutron irradiation treatment. > READ MORE